Diagnostics and treatment the deficiency of biotinidase in practice of the children’s neurologist

封面

如何引用文章

全文:

详细

Biotinidase deficiency is a hereditary metabolic disease from the group of organic acidurias with an autosomal recessive type of inheritance. The disease is caused by mutations in the BTD gene, which encodes an enzyme biotinidase. Deficiency of biotinidase leads to insufficiency of intracellular Biotin, which is the coenzyme of four carboxylases involved in gluconeogenesis, leucine metabolism and biosynthesis of fatty acids. At infringement of function of carboxylase accumulate substrates that are toxic to the human body. Deficiency of biotinidase is manifested primarily by neurocutaneous disorders. The Central nervous system is particularly vulnerable, since the activity of biotinidase in the human brain is very low and therefore, for the normal functioning of neurons, it is necessary to receive enough biotin through the blood-brain barrier. With its deficiency, neurological disorders for a certain period may be the only sign of the disease. Symptoms can be successfully cured or prevented by the introduction of pharmacological doses of biotin. The article presents two clinical observations of young children with biotinidase deficiency, the main manifestation of which in the first clinical case were neurological disorders, in the second – respiratory disorders. To confirm the diagnosis, an enzyme diagnosis was carried out, which revealed a low level of biotinidase. The rapid and pronounced efficacy of biotin therapy with cessation of attacks, the possibility of cancellation of anticonvulsants, regression of neurological, skin and respiratory disorders.

作者简介

Oksana Poteshkina

North-Western State Medical University named after I.I. Mechnikov

编辑信件的主要联系方式.
Email: ovpoteshkina@gmail.com

MD, PhD, Associate Professor, Department of Pediatric Neurology and Neurosurgery

俄罗斯联邦, Saint Petersburg

Julia Artyushkina

City Children’s Hospital No 1

Email: karaulova_u@mail.ru

Neurologist

俄罗斯联邦, Saint Petersburg

Ludmila Shchugareva

North-Western State Medical University named after I.I. Mechnikov

Email: neurodoctor@mail.ru

MD, PhD, Dr Med Sci, Associate Professor, Department of pediatric neurology and neurosurgery

俄罗斯联邦, Saint Petersburg

Andrei Povzun

City Children’s Hospital No 1

Email: a.a.povzun@gmail.com

Neurologist

俄罗斯联邦, Saint Petersburg

Ekaterina Savelyeva

City Children’s Hospital No 1

Email: Katya_sav85@mail.ru

Рediatrician

俄罗斯联邦, Saint Petersburg

Dmitri Ivanov

City Children’s Hospital No 1

Email: Idv68@list.ru

Рediatrician

俄罗斯联邦, Saint Petersburg

参考

  1. Малов А.Г., Овчинникова Е.С., Серебренникова Э.Б. Проблемы нозологической диагностики эпилепсии при врожденных нарушениях метаболизма // Неврологический журнал. – 2013. – Т. 18. – № 5. – С. 31–33. [Malov AG, Ovchinnikova ES, Serebrennikova EB. The problems of nosological diagnosis of epilepsy in inborn metabolic diseases. Neurological Journal. 2013;18(5): 31-33. (In Russ.)]
  2. Михайлова С.В., Захарова Е.Ю., Ильина Е.С., Петрухин А.С. Диагностика и лечение недостаточности биотинидазы у детей раннего возраста // Лечащий врач. – 2005. – № 6. – C. 79–82. [Mikhailova SV, Zakharova EY, Il’ina ES, Petrukhin AS. Diagnosis and treatment of biotinidase deficiency in young children. Lechaschi Vrach Journal. 2005;(6):79-82. (In Russ.)]
  3. Михайлова С.В., Захарова Е.Ю., Петрухин А.С. Нейрометаболические заболевания у детей и подростков: диагностика и подходы к лечению. – М., 2017. [Mikhaylova SV, Zakharova EY, Petrukhin AS. Neurometabolic diseases in children and adolescents: diagnosis and treatment approaches. Moscow; 2017. (In Russ.)]
  4. Наследственные нарушения нервно-психического развития детей / Под ред. П.А. Темина, Л.З. Казанцевой. – М., 2001. – С. 193–217. [Temin PA, Kazan tseva LZ, editors. Hereditary disorders of the neuropsychological development of children. Moscow; 2001. P. 193-217. (In Russ.)]
  5. Cowan TM, Blitzer MG, Wolf B, Working Group of the American College of Medical Genetics Laboratory Quality Assurance C. Technical standards and guidelines for the diagnosis of biotinidase deficiency. Genet Med. 2010;12(7):464-470. doi: 10.1097/GIM.0b013e3181e4cc0f.
  6. Gannavarapu S, Prasad C, DiRaimo J, et al. Biotinidase deficiency: Spectrum of molecular, enzymatic and clinical information from newborn screening Ontario, Canada (2007-2014). Mol Genet Metab. 2015;116(3):146-151. doi: 10.1016/j.ymgme.2015.08.010.
  7. Monnot S, Serre V, Chadefaux-Vekemans B, et al. Structural insights on pathogenic effects of novel mutations causing pyruvate carboxylase deficiency. Hum Mutat. 2009;30(5):734-740. doi: 10.1002/humu.20908.
  8. Moslinger D, Stockler-Ipsiroglu S, Scheibenreiter S, et al. Clinical and neuropsychological outcome in 33 patients with biotinidase deficiency ascertained by nationwide newborn screening and family studies in Austria. Eur J Pediatr. 2001;160(5):277-282. doi: 10.1007/s004310100740.
  9. Pomponio RJ, Hymes J, Reynolds TR, et al. Mutations in the human biotinidase gene that cause profound biotinidase deficiency in symptomatic children: molecular, biochemical, and clinical analysis. Pediatr Res. 1997;42(6):840-848. doi: 10.1203/00006450-199712000-00020.
  10. Rahman S, Standing S, Dalton RN, Pike MG. Late presentation of biotinidase deficiency with acute visual loss and gait disturbance. Dev Med Child Neurol. 1997;39(12):830-831. doi: 10.1111/j.1469-8749.1997.tb07552.x.
  11. Roger G, Bureau M, Dravet Ch, et al. Epileptic syndromes in infancy, childhood and adolescence. Montrouge: John Libbey Eurotext; 2005.
  12. Scriver CR, Beaudet AL, Sly WS. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001.
  13. Bradford L, Therrel BL. U.S. newborn screening policy dilemmas for the twenty-first century. Mol Genet Metab. 2001;74(1-2):64-74. doi: 10.1006/mgme.2001.3238.
  14. Wiznitzer M, Bangert BA. Biotinidase deficiency: clinical and MRI findings consistent with myelopathy. Pediatr Neurol. 2003;29(1):56-58. doi: 10.1016/s0887-8994(03)00042-0.
  15. Wolf B. Biotinidase deficiency: “if you have to have an inherited metabolic disease, this is the one to have”. Genet Med. 2012;14(6):565-575. doi: 10.1038/gim.2011.6.
  16. Wolf B. Biotinidase Deficiency: New Directions and Practical Concerns. Curr Treat Options Neurol. 2003;5(4): 321-8. doi: 10.1007/s11940-003-0038-4.
  17. Wolf B. Successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening. Genet Med. 2017;19(4):396-402. doi: 10.1038/gim.2016.135.
  18. Wolf B. The neurology of biotinidase deficiency. Mol Genet Metab. 2011;104(1-2):27-34. doi: 10.1016/j.ymgme.2011.06.001.

版权所有 © Poteshkina O.V., Artyushkina J.N., Shchugareva L.M., Povzun A.A., Savelyeva E.A., Ivanov D.V., 2018

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 


##common.cookie##